Market capitalization | $4.82b |
Enterprise Value | $4.98b |
P/E (TTM) P/E ratio | 4,049.30 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.87 |
P/S ratio (TTM) P/S ratio | 13.44 |
P/B ratio (TTM) P/B ratio | 25.36 |
Revenue growth (TTM) Revenue growth | 137.47% |
Revenue (TTM) Revenue | $358.76m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
10 Analysts have issued a TransMedics Group, Inc. forecast:
10 Analysts have issued a TransMedics Group, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 359 359 |
137%
137%
|
|
Gross Profit | 218 218 |
109%
109%
|
|
EBITDA | 41 41 |
524%
524%
|
EBIT (Operating Income) EBIT | 26 26 |
272%
272%
|
Net Profit | 3 3 |
117%
117%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.
Head office | United States |
CEO | Waleed Hassanein |
Employees | 584 |
Founded | 1998 |
Website | www.transmedics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.